Jan 27, 2009 - Inspire Pharmaceuticals, Inc. announced today it has reached agreement with the U.S. FDA through a Special Protocol Assessment (SPA) on the design of a Phase 3 clinical trial for Prolacria (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease and has recently initiated enrollment in the trial.
The details can be read here.
No comments:
Post a Comment